A detailed history of Jpmorgan Chase & CO transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,874 shares of INMB stock, worth $28,195. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,874
Previous 5,202 12.92%
Holding current value
$28,195
Previous $45,000 31.11%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$4.86 - $9.86 $3,265 - $6,625
672 Added 12.92%
5,874 $31,000
Q2 2024

Aug 12, 2024

BUY
$7.15 - $11.84 $37,194 - $61,591
5,202 New
5,202 $45,000
Q4 2023

Feb 12, 2024

BUY
$6.6 - $11.52 $22,961 - $40,078
3,479 New
3,479 $39,000

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $86.1M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.